Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Readmissions for Cardiac and Non-cardiac Causes Among those with Epilepsy or Multiple Sclerosis
Epilepsy/Clinical Neurophysiology (EEG)
P14 - Poster Session 14 (8:00 AM-9:00 AM)
12-008

To determine proportions of cardiac readmissions in epilepsy compared to multiple sclerosis (MS) or population with neither condition.

Studies suggest that certain antiseizure medications are associated with increase in serological cardiovascular disease (CVD) markers which could increase cardiac-related admissions and mortality.
We used the 2014 National Readmissions Database and validated ICD-9-CM codes to identify patients with epilepsy (N=202,938) and MS (N=29,559) aged 18 years and older. Primary outcomes of interest were: 1) 30-day readmissions due to cardiac causes; 2) 30-day readmissions due to other causes; and 3) no 30-day readmissions. Predictors of 30-day readmissions for cardiac causes in epilepsy were examined using multinomial logistic regression after adjusting for sex, household income, primary payer, discharge disposition, admission type and comorbidity (Charlson).
The proportion of 30-day readmissions for epilepsy vs. MS were: 1) due to cardiac causes (0.17% vs. 0.13%); 2) due to other causes (0.27% vs. 0.20%). The odds of 30-day cardiac readmissions in epilepsy and MS were lower compared to those without either conditions (OR=0.64, 95%CI 0.57-0.73, p<0.0001; OR=0.60, 95%CI 0.43-0.84, p=0.003). The odds of non-cardiac readmissions were higher in both epilepsy and MS (OR=1.45, 95%CI 1.42-1.47, p<0.0001; OR=1.3, 95%CI 1.24-1.37, p<0.0001). Among those with epilepsy, increasing age and Charlson index ≥3 were associated with higher odds of 30-day cardiac readmissions. A higher proportion of those with epilepsy readmitted within 30 days due to cardiac causes died in hospital (10.09%) than those with MS (6.42%) or those without either condition (5.61%).

Hospital readmissions for cardiac disease are lower while those for other causes are higher in people with epilepsy or MS. However, epilepsy patients readmitted for cardiac causes had higher odds of dying in hospital. These findings need to be further explored to help in the identification of treatments that could reduce mortality in epilepsy.

Authors/Disclosures
Hernan Nicolas Lemus Esquivel, MD (The University of Alabama at Birmingham)
PRESENTER 		Dr. Lemus Esquivel has nothing to disclose.
Parul Agarwal Parul Agarwal has nothing to disclose.
Churl-Su Kwon, MBBS (Columbia University) Dr. Kwon has nothing to disclose.
Anusha Yeshokumar, MD (Icahn School of Medicine at Mount Sinai) Dr. Yeshokumar has nothing to disclose.
Mandip S. Dhamoon, MD, MPH Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Faegre Baker Daniels LLP. Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wellstar Health System Inc. Dr. Dhamoon has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Fabiani Cohen & Hall, LLP. Dr. Dhamoon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Kramer, Dillof, Livingston & Moore. Dr. Dhamoon has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Robins Kaplan. Dr. Dhamoon has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Parker Waichman LLP. Dr. Dhamoon has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Heidell, Pittoni, Murphy & Bach, LLP.
No disclosure on file
Nathalie Jette, MD, MSc, FRCPC, FÂ鶹´«Ã½Ó³»­ (University of Calgary) Dr. Jette has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE Epilepsia. The institution of Dr. Jette has received research support from NIH. The institution of Dr. Jette has received research support from AES.